Your browser doesn't support javascript.
loading
Mapping the spatial dynamics of the CD4+ T cell spectrum in classical Hodgkin lymphoma.
Menéndez, Victoria; Solórzano, José L; García-Cosío, Mónica; Cereceda, Laura; Díaz, Eva; Estévez, Mónica; Roncador, Giovanna; Vega, Zaira; Montalbán, Carlos; Kulasinghe, Arutha; García, Juan F.
Afiliación
  • Menéndez V; Translational Research, Fundación MD Anderson International España S.L. Madrid, 28033 Madrid, Spain.
  • Solórzano JL; Translational Research, Fundación MD Anderson International España S.L. Madrid, 28033 Madrid, Spain; Pathology Department, MD Anderson Cancer Center Madrid, Madrid, Spain.
  • García-Cosío M; Pathology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Cereceda L; Translational Research, Fundación MD Anderson International España S.L. Madrid, 28033 Madrid, Spain; Pathology Department, MD Anderson Cancer Center Madrid, Madrid, Spain.
  • Díaz E; Translational Research, Fundación MD Anderson International España S.L. Madrid, 28033 Madrid, Spain.
  • Estévez M; Hematology Department, MD Anderson Cancer Center Madrid, Madrid, Spain.
  • Roncador G; Monoclonal Antibodies and Histopathology Units, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
  • Vega Z; Monoclonal Antibodies and Histopathology Units, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
  • Montalbán C; Translational Research, Fundación MD Anderson International España S.L. Madrid, 28033 Madrid, Spain.
  • Kulasinghe A; Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, Australia.
  • García JF; Translational Research, Fundación MD Anderson International España S.L. Madrid, 28033 Madrid, Spain; Pathology Department, MD Anderson Cancer Center Madrid, Madrid, Spain. Electronic address: jfgarcia@mdanderson.es.
Mod Pathol ; : 100551, 2024 Jun 25.
Article en En | MEDLINE | ID: mdl-38936478
ABSTRACT
As around 25-30% of classical Hodgkin Lymphoma (cHL) patients with advanced stages do not respond to standard therapies, the tumor microenvironment (TME) of cHL is one avenue that may be explored with the aim of improving risk stratification. CD4+ T cells are thought to be one of the main cell types in the TME. However, few immune signatures have been studied, and many of these lack related spatial data. Thus, our aim is to spatially resolve the CD4+ T cell subtypes that influence cHL outcome, depicting new immune signatures or transcriptional patterns that are in crosstalk with the tumor cells. This study was conducted using the Nanostring GeoMx DSP technology, based on the selection of distinct functional areas of patients' tissues followed by the gene-expression profiling. The goals were to assess the differences in CD4+ T cell populations between tumor-rich and immune-predominant areas defined by different CD30 and PD-L1 expression levels and to seek correlations with clinical metadata. Our results depict a complex map of CD4+ T cells with different functions and differentiation states that are enriched at distinct locations, the flux of cytokines and chemokines that could be related to these, and the specific relationships with the clinical outcome.

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Mod Pathol Asunto de la revista: PATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Mod Pathol Asunto de la revista: PATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: España